M5 muscarinic receptor Inhibitors
1 drugsAbout M5 muscarinic receptor
The M5 muscarinic receptor is a G protein-coupled receptor that binds acetylcholine, influencing neuronal excitability and synaptic plasticity. Upon activation, it triggers intracellular signaling cascades, playing a role in various physiological processes. Research continues to elucidate its functions.
The M5 receptor is a potential drug target, though there is currently no genetic evidence directly linking it to specific diseases. Further research is needed to validate its role in disease pathology and unlock its full therapeutic potential.
Currently, one FDA-approved drug, darifenacin, interacts with muscarinic receptors and was first approved in 2017. This small molecule drug is marketed by Macleods Pharms Ltd for other therapeutic areas.
Top M5 muscarinic receptor Drugs
Macleods Pharms Ltd is the only company with an approved drug targeting this receptor.
Low competition suggests an opportunity for new entrants, but also highlights potential challenges.
M5 muscarinic receptor Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets M5 muscarinic receptor, using small molecule modality.
The lack of diverse modalities represents a whitespace opportunity for novel biologics.
M5 muscarinic receptor Clinical Trials 8 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on M5 muscarinic receptor. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 | 100% |
| Phase 2 | 2 | 0 | 1 | 1 | 0% |
| Phase 3 | 1 | 1 | 0 | 0 | 100% |
| Phase 4 | 3 | 2 | 1 | 0 | 67% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
M5 muscarinic receptor Drug Approval Timeline (2017 - 2017)
The first and most recent drug approval was darifenacin in 2017.
A single approval in the past few years indicates a potentially unsaturated market with room for growth.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 8 (3 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on M5 muscarinic receptor. A trial counts if an approved drug acting on M5 muscarinic receptor is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.